Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.

The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer Inc. raised its profit forecast for the year, with the drugmaker’s ongoing cost cuts helping to make up for a lack of ...

Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant reported better-than ...

Pfizer's stock surged following a report of stronger-than-expected earnings, driven by robust sales of COVID-19 products and ...

Q2 2025 Management View Albert Bourla, Chairman and CEO, highlighted progress in R&D, expansion of the commercial portfolio, and improved margins, stating the company is “raising our adjusted diluted ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Trump sent a letter to 17 drug companies demanding a commitment to lower prices in the next 60 days through a series of ...